Equities

OXB

OXB

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (GBX)413.50
  • Today's Change1.00 / 0.24%
  • Shares traded44.22k
  • 1 Year change+115.36%
  • Beta1.5921
Data delayed at least 20 minutes, as of Nov 21 2024 13:12 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Key statistics

As of last trade OXB (OXB:LSE) traded at 413.50, -8.11% below its 52-week high of 450.00, set on Oct 28, 2024.
52-week range
Today
164.29Dec 01 2023450.00Oct 28 2024
Short selling activity
Low
Med
High
Provided by S&P Global Market Intelligence
Open400.50
High415.00
Low400.50
Bid411.50
Offer413.50
Previous close412.50
Average volume218.96k
Shares outstanding105.92m
Free float80.62m
P/E (TTM)--
Market cap436.93m GBP
EPS (TTM)-1.44
GBP
Data delayed at least 20 minutes, as of Nov 21 2024 13:12 GMT.
More ▼

Investors Chronicle View

The last IC recommendation on OXB shares was Hold at 357.00 on 23 Sep 2024Read the full article

Board of Directors

1/11

Dr. Roch Doliveux, Chairman

2/11

Dr. Frank Mathias, Chief Executive Officer

3/11

Stuart Henderson, Vice Chairman

4/11

Professor Dame Kay Davies, Senior Independent Director

5/11

Dr. Lucinda Crabtree, Chief Financial Officer

6/11

Laurence Espinasse, Non-Executive Director

7/11

Robert Ghenchev, Non-Executive Director

8/11

Namrata P Patel, Independent Non-Executive Director

9/11

Leone Patterson, Independent Non-Executive Director

10/11

Dr. Heather Preston, Independent Non-Executive Director

11/11

Peter Soelkner, Independent Non-Executive Director

Contact

Headquarters and registered address:
Oxford BioMedica plc
Windrush Court
Transport Way
Oxford
OX4 6LT
United Kingdom

T: +44 (0) 1865 783 000

2024 Interim Results

Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.
S&P Global Market Intelligence Short Selling Activity © S&P Global Market Intelligence. All rights reserved.
Although S&P Global Market Intelligence has made every effort to ensure this data is correct, nevertheless no guarantee is given to the accuracy or completeness. Any opinions or estimates expressed herein are those of S&P Global Market Intelligence on the date of preparation and are subject to change without notice; however no such opinions or estimates constitute legal, investment or other advice. You must therefore seek independent legal, investment or other appropriate advice from a suitably qualified and/or authorised and regulated advisor prior to making any legal, investment or other decision. This is intended for information purposes only and is not intended as an offer or recommendation to buy, sell or otherwise deal in securities.